Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright

Unity Biotechnology (NASDAQ:UBX) had its target price lowered by HC Wainwright from $8.00 to $4.00 in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Separately, Chardan Capital reissued a “buy” rating and issued a $6.00 price objective on shares of Unity Biotechnology in a report on Monday, March 10th.

Unity Biotechnology Stock Down 28.8 %

Shares of NASDAQ:UBX opened at $1.30 on Monday. Unity Biotechnology has a 52-week low of $0.94 and a 52-week high of $3.10. The stock has a market cap of $21.93 million, a P/E ratio of -0.99 and a beta of 1.02. The business has a fifty day moving average of $1.91 and a two-hundred day moving average of $1.51.

Institutional Investors Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC lifted its holdings in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 50,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.